Gene-environment interactions in the associations of PFAS exposure with insulin sensitivity and beta-cell function in a Faroese cohort followed from birth to adulthood.


Journal

Environmental research
ISSN: 1096-0953
Titre abrégé: Environ Res
Pays: Netherlands
ID NLM: 0147621

Informations de publication

Date de publication:
01 06 2023
Historique:
received: 16 11 2022
revised: 26 02 2023
accepted: 28 02 2023
pmc-release: 01 06 2024
medline: 17 4 2023
pubmed: 4 3 2023
entrez: 3 3 2023
Statut: ppublish

Résumé

Exposure to perfluoroalkyl substances (PFAS) has been associated with changes in insulin sensitivity and pancreatic beta-cell function in humans. Genetic predisposition to diabetes may modify these associations; however, this hypothesis has not been yet studied. To evaluate genetic heterogeneity as a modifier in the PFAS association with insulin sensitivity and pancreatic beta-cell function, using a targeted gene-environment (GxE) approach. We studied 85 single-nucleotide polymorphisms (SNPs) associated with type 2 diabetes, in 665 Faroese adults born in 1986-1987. Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) were measured in cord whole blood at birth and in participants' serum from age 28 years. We calculated the Matsuda-insulin sensitivity index (ISI) and the insulinogenic index (IGI) based on a 2 h-oral glucose tolerance test performed at age 28. Effect modification was evaluated in linear regression models adjusted for cross-product terms (PFAS*SNP) and important covariates. Prenatal and adult PFOS exposures were significantly associated with decreased insulin sensitivity and increased beta-cell function. PFOA associations were in the same direction but attenuated compared to PFOS. A total of 58 SNPs were associated with at least one PFAS exposure variable and/or Matsuda-ISI or IGI in the Faroese population and were subsequently tested as modifiers in the PFAS-clinical outcome associations. Eighteen SNPs showed interaction p-values (P Findings from this study suggest that PFAS-associated changes in insulin sensitivity could vary between individuals as a result of genetic predisposition and warrant replication in independent larger populations.

Sections du résumé

BACKGROUND
Exposure to perfluoroalkyl substances (PFAS) has been associated with changes in insulin sensitivity and pancreatic beta-cell function in humans. Genetic predisposition to diabetes may modify these associations; however, this hypothesis has not been yet studied.
OBJECTIVES
To evaluate genetic heterogeneity as a modifier in the PFAS association with insulin sensitivity and pancreatic beta-cell function, using a targeted gene-environment (GxE) approach.
METHODS
We studied 85 single-nucleotide polymorphisms (SNPs) associated with type 2 diabetes, in 665 Faroese adults born in 1986-1987. Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) were measured in cord whole blood at birth and in participants' serum from age 28 years. We calculated the Matsuda-insulin sensitivity index (ISI) and the insulinogenic index (IGI) based on a 2 h-oral glucose tolerance test performed at age 28. Effect modification was evaluated in linear regression models adjusted for cross-product terms (PFAS*SNP) and important covariates.
RESULTS
Prenatal and adult PFOS exposures were significantly associated with decreased insulin sensitivity and increased beta-cell function. PFOA associations were in the same direction but attenuated compared to PFOS. A total of 58 SNPs were associated with at least one PFAS exposure variable and/or Matsuda-ISI or IGI in the Faroese population and were subsequently tested as modifiers in the PFAS-clinical outcome associations. Eighteen SNPs showed interaction p-values (P
DISCUSSION
Findings from this study suggest that PFAS-associated changes in insulin sensitivity could vary between individuals as a result of genetic predisposition and warrant replication in independent larger populations.

Identifiants

pubmed: 36868448
pii: S0013-9351(23)00392-4
doi: 10.1016/j.envres.2023.115600
pmc: PMC10101920
mid: NIHMS1884031
pii:
doi:

Substances chimiques

Alkanesulfonic Acids 0
Alpha-Ketoglutarate-Dependent Dioxygenase FTO EC 1.14.11.33
Environmental Pollutants 0
Fluorocarbons 0
FTO protein, human EC 1.14.11.33
perfluorooctane sulfonic acid 9H2MAI21CL
perfluorooctanoic acid 947VD76D3L
SLC12A3 protein, human 0
Solute Carrier Family 12, Member 3 0
Insulin 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115600

Subventions

Organisme : NIEHS NIH HHS
ID : P30 ES023515
Pays : United States
Organisme : NIEHS NIH HHS
ID : P42 ES027706
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES021477
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES029328
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Damaskini Valvi reports financial support was provided by National Institute of Environmental Health Sciences. Philippe Grandjean reports a relationship with PFAS-exposed communities that includes: consulting or advisory. Damaskini Valvi reports financial support was provided by National Institute of Environmental Health Sciences. Philippe Grandjean reports financial support was provided by National Institute of Environmental Health Sciences. Pal Weihe reports financial support was provided by Faroese Research Council. Philippe Grandjean reports financial support was provided by Danish Environmental Protection Agency. Karine Audouze reports financial support was provided by European Union Horizon program. Philippe Grandjean reports a relationship with PFAS-exposed communities that includes: paid expert testimony.

Références

Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Hum Mol Genet. 2000 Oct 12;9(17):2517-21
pubmed: 11030756
PLoS Genet. 2010 Aug 26;6(8):
pubmed: 20865176
Curr Diab Rep. 2010 Dec;10(6):485-97
pubmed: 20886378
Sci Rep. 2016 Nov 24;6:37769
pubmed: 27883041
Environ Int. 2020 Jan;134:105244
pubmed: 31711019
J Clin Endocrinol Metab. 2008 Jun;93(6):2294-9
pubmed: 18364377
Obes Facts. 2010 Jun;3(3):173-80
pubmed: 20616607
Environ Sci Process Impacts. 2020 Dec 16;22(12):2307-2312
pubmed: 33230514
Genes (Basel). 2021 Feb 03;12(2):
pubmed: 33546406
Lancet. 2018 Jun 16;391(10138):2463-2474
pubmed: 29916387
J Clin Endocrinol Metab. 2007 Jun;92(6):2358-62
pubmed: 17374705
Environ Health Perspect. 2022 Apr;130(4):46001
pubmed: 35475652
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
BMC Med Genet. 2006 May 05;7:44
pubmed: 16677372
J Agric Food Chem. 2017 Jan 25;65(3):533-543
pubmed: 28052194
Science. 2007 Jun 1;316(5829):1341-5
pubmed: 17463248
Respir Med. 2010 Jun;104(6):889-94
pubmed: 20153157
Environ Health Perspect. 2018 Mar 01;126(3):037001
pubmed: 29498927
Nature. 2016 Aug 4;536(7614):41-47
pubmed: 27398621
J Clin Endocrinol Metab. 2009 Jan;94(1):190-6
pubmed: 18984671
Diabetes. 2006 Sep;55(9):2649-53
pubmed: 16936217
Environ Sci Technol. 2018 Mar 20;52(6):3738-3747
pubmed: 29516726
Neurol Sci. 2014 Nov;35(11):1701-6
pubmed: 24816679
Reprod Toxicol. 2017 Mar;68:3-33
pubmed: 27760374
Nat Rev Endocrinol. 2014 Jan;10(1):51-61
pubmed: 24247219
J Cell Mol Med. 2018 Mar;22(3):1720-1732
pubmed: 29314660
Diabetes. 2007 Jan;56(1):256-64
pubmed: 17192490
Environ Int. 2020 Mar;136:105435
pubmed: 31935559
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Toxicol Sci. 2011 Sep;123(1):290-303
pubmed: 21705711
PLoS One. 2014 Jun 30;9(6):e101329
pubmed: 24978468
Diabetologia. 2019 Oct;62(10):1811-1822
pubmed: 31451869
J Expo Sci Environ Epidemiol. 2023 Jan;33(1):40-55
pubmed: 35970987
Genet Epidemiol. 2015 Nov;39(7):518-28
pubmed: 26411674
Environ Int. 2019 Sep;130:104874
pubmed: 31200157
PLoS Genet. 2012;8(6):e1002765
pubmed: 22737082
J Clin Endocrinol Metab. 2008 Aug;93(8):3136-41
pubmed: 18477659
Diabetes. 2008 Nov;57(11):3122-8
pubmed: 18694974
Toxicol Environ Chem. 2020;102(1-4):1-36
pubmed: 33304027
Diabetes. 2009 Mar;58(3):750-6
pubmed: 19074981
Kidney Int Suppl. 2007 Aug;(106):S43-8
pubmed: 17653210
Toxicol In Vitro. 2020 Feb;62:104700
pubmed: 31676336
J Diabetes Investig. 2013 May 6;4(3):233-44
pubmed: 24843659
Sci Total Environ. 2019 Feb 25;653:359-369
pubmed: 30412881
Ann N Y Acad Sci. 2002 Jun;967:7-18
pubmed: 12079830
Eur J Hum Genet. 2008 May;16(5):652-6
pubmed: 18231124
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Am J Epidemiol. 2000 Jan 15;151(2):190-8
pubmed: 10645822
Nat Genet. 2009 Jan;41(1):35-46
pubmed: 19060910
PLoS One. 2013 Aug 14;8(8):e70792
pubmed: 23967108
Environ Int. 2019 Feb;123:390-398
pubmed: 30622063
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Sci Rep. 2013;3:2712
pubmed: 24048418
J Clin Endocrinol Metab. 2021 Jul 13;106(8):2495-2504
pubmed: 33890111
Diabetes. 2006 Mar;55(3):651-8
pubmed: 16505227
Nat Genet. 2020 Jul;52(7):680-691
pubmed: 32541925
Circ Res. 2016 May 27;118(11):1723-35
pubmed: 27230638
Nature. 2007 Jun 7;447(7145):661-78
pubmed: 17554300
Environ Int. 2013 Jul;57-58:2-10
pubmed: 23624243
Environ Health Perspect. 2021 Sep;129(9):97002
pubmed: 34468161
Arch Environ Health. 1992 May-Jun;47(3):185-95
pubmed: 1596101
J Clin Endocrinol Metab. 2014 Apr;99(4):E608-14
pubmed: 24606078
PLoS One. 2015 Oct 29;10(10):e0140908
pubmed: 26512983
Nat Commun. 2021 Jan 5;12(1):24
pubmed: 33402679
Diabetes. 2008 Apr;57(4):1136-42
pubmed: 18192539
JAMA Netw Open. 2018 Aug 3;1(4):e181493
pubmed: 30646133
Nat Genet. 2008 Feb;40(2):189-97
pubmed: 18193044
Environ Sci Technol. 2017 Nov 21;51(22):13388-13396
pubmed: 29056041
J Clin Endocrinol Metab. 2004 May;89(5):2019-23
pubmed: 15126514
Med Sci Sports Exerc. 2008 Jan;40(1):25-33
pubmed: 18091023
J Expo Sci Environ Epidemiol. 2013 Mar;23(2):151-5
pubmed: 23093101
Int J Mol Sci. 2020 Aug 30;21(17):
pubmed: 32872570

Auteurs

Damaskini Valvi (D)

Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States. Electronic address: dania.valvi@mssm.edu.

David C Christiani (DC)

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States.

Brent Coull (B)

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Kurt Højlund (K)

Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.

Flemming Nielsen (F)

Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.

Karine Audouze (K)

Université Paris Cité, INSERM UMR-S1124, Paris, France.

Li Su (L)

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States.

Pal Weihe (P)

Department of Occupational Medicine and Public Health, The Faroese Hospital System, Tórshavn, Faroe Islands; Centre of Health Science, Faculty of Health Sciences, University of the Faroe Islands, Tórshavn, Faroe Islands.

Philippe Grandjean (P)

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH